Marvel Biosciences Corp.
MBCOF
$0.0629
-$0.0021-3.23%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.80% | -34.88% | -36.29% | -18.65% | 17.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.94% | -57.41% | -44.85% | 9.31% | 56.44% |
| Operating Income | 45.94% | 57.41% | 44.85% | -9.31% | -56.44% |
| Income Before Tax | 35.51% | 44.59% | 29.02% | -13.65% | -61.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.51% | 44.59% | 29.02% | -13.65% | -61.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.51% | 44.59% | 29.02% | -13.65% | -61.30% |
| EBIT | 45.94% | 57.41% | 44.85% | -9.31% | -56.44% |
| EBITDA | -- | -- | -- | 40.94% | -12.55% |
| EPS Basic | 39.02% | 46.06% | 29.53% | -6.50% | -41.69% |
| Normalized Basic EPS | 38.91% | 46.08% | 29.10% | -6.96% | -42.23% |
| EPS Diluted | 39.02% | 46.06% | 29.53% | -6.50% | -41.69% |
| Normalized Diluted EPS | 38.91% | 46.08% | 29.10% | -6.96% | -42.23% |
| Average Basic Shares Outstanding | 6.73% | 3.59% | 0.76% | 4.61% | 9.80% |
| Average Diluted Shares Outstanding | 6.73% | 3.59% | 0.76% | 4.61% | 9.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |